Roche signs definitive merger agreement to buy PathAI in bid to advance AI-powered diagnostics

Roche has confirmed a definitive merger agreement to purchase PathAI, a US company working in digital pathology and AI-powered technology for pathology labs and the biopharma sector. The deal follows a productive working relationship between the two organisations that began in 2021 and was broadened in 2024 to cover the development of AI-enabled companion diagnostic algorithms. Once the transaction closes, which is anticipated in the latter half of the year, PathAI will be folded into Roche’s diagnostics division.

The purchase bolsters Roche’s standing in digital pathology, a discipline that is converting traditionally manual, time-intensive workflows into automated, AI-guided processes. The technology works by producing high-resolution digital images from physical tissue slides, giving pathologists access to AI tools that simplify diagnostic processes and help get results to patients more quickly.

“Digital pathology has the potential to improve precision diagnosis of cancer and enable physicians to offer better tailored treatment regimens,” said Matt Sause, CEO of Roche Diagnostics. “Bringing PathAI into Roche Diagnostics will allow us to combine their best-in-class digital pathology tools with our leading oncology diagnosis platforms to deliver better insights for physicians and potentially better outcomes for patients worldwide.”

“Joining forces with Roche marks a new era for PathAI, enabling us to realise our mission of improving patient outcomes through AI-powered pathology at unprecedented scale and speed,” said Andy Beck, CEO and co-founder of PathAI. “Roche’s global infrastructure and expertise will bring our digital diagnostics technology to patients worldwide.”

PathAI’s AISight image management software provides a smooth, intuitive experience, weaving together sophisticated analysis and operational tools within the digital pathology lab environment. Roche plans to roll this solution out on a global scale across what is a fast-expanding pathology market.

The combined strengths of both organisations also reinforce Roche’s position in precision medicine by bolstering its biopharma service offering. PathAI brings considerable know-how in AI-led solutions spanning clinical trial support and translational research, which pairs well with Roche’s long-standing expertise in companion diagnostics. Together, these strengths are expected to speed up the identification of new biomarkers, potential drug targets and new diagnostic tools, adding greater value for biopharma partners and pushing the wider transition from broad-based treatment toward care that is tailored to the individual patient.

---

---

Related Topics and Keywords

AI-powered diagnostics, definitive merger agreement, PathAI, Roche